Coverage of Lateral Lymph Nodes in Rectal Cancer Patients with Routine Radiation Therapy Practice and Associated Locoregional Recurrence Rates

Dutch Snapshot Research Group, Tania C. Sluckin, Sanne Marije J.A. Hazen, Karin Horsthuis, Regina G.H. Beets-Tan, Imogeen E. Antonisse, Maaike Berbée, Liselotte W. van Bockel, Anniek H. Boer, Heleen M. Ceha, Jeltsje S. Cnossen, Elisabeth D. Geijsen, Mariska D. den Hartogh, Ellen M. Hendriksen, Martijn P.W. Intven, Mathilde M. Leseman-Hoogenboom, Philip Meijnen, Karin Muller, Vera Oppedijk, Tom RozemaHeidi Rütten, Patty H. Spruit, Tanja C. Stam, Laura A. Velema, An Sofie E. Verrijssen, Johanna Vos-Westerman, Pieter J. Tanis, Corrie A.M. Marijnen, Miranda Kusters*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    3 Citations (Scopus)
    15 Downloads (Pure)


    Purpose: Involved internal iliac and obturator lateral lymph nodes (LLNs) are a known risk factor for the occurrence of ipsilateral local recurrences (LLR) in rectal cancer. This study examined coverage of LLNs with routine radiation therapy practice in the Netherlands and associated LLR rates. Methods and Materials: Patients with a primary tumor ≤8 cm of the anorectal junction, cT3-4 stage, and at least 1 internal iliac or obturator LLN with short axis ≥5 mm who received neoadjuvant (chemo)radiation therapy, were selected from a national, cross-sectional study of patients with rectal cancer treated in the Netherlands in 2016. Magnetic resonance images and radiation therapy treatment plans were reviewed regarding segmented LLNs as gross tumor volume (GTV), location of LLNs within clinical target volume (CTV), and received proportion of the planned radiation therapy dose. Results: A total of 223 out of 3057 patients with at least 1 LLN ≥5 mm were selected. Of those, 180 (80.7%) LLNs were inside the CTV, of which 60 (33.3%) were segmented as GTV. Overall, 202 LLNs (90.6%) received ≥95% of the planned dose. Four-year LLR rates were not significantly higher for LLNs situated outside the CTV compared with those inside (4.0% vs 12.5%, P =.092) or when receiving <95% versus ≥95% of the planned radiation therapy dose (7.1% vs 11.3%, P =.843), respectively. Two of 7 patients who received a dose escalation of 60 Gy developed an LLR (4-year LLR rate of 28.6%). Conclusions: This evaluation of routine radiation therapy practice showed that adequate coverage of LLNs was still associated with considerable 4-year LLR rates. Techniques resulting in better local control for patients with involved LLNs need to be explored further.

    Original languageEnglish
    Pages (from-to)422-433
    Number of pages12
    JournalInternational Journal of Radiation Oncology Biology Physics
    Issue number2
    Publication statusPublished - 1-Oct-2023

    Cite this